Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era

被引：76

作者：

Gerson, James N. ^{[1
]}

Handorf, Elizabeth ^{[1
]}

Villa, Diego ^{[2
]}

Gerrie, Alina S. ^{[2
]}

Chapani, Pary ^{[2
]}

Li, Shaoying ^{[3
]}

Medeiros, L. Jeffrey ^{[3
]}

Wang, Michael, I ^{[3
]}

Cohen, Jonathon B. ^{[4
]}

Calzada, Oscar ^{[4
]}

Churnetski, Michael C. ^{[4
]}

Hill, Brian T. ^{[5
]}

Sawalha, Yazeed ^{[5
]}

Hernandez-Ilizaliturri, Francisco J. ^{[6
]}

Kothari, Shalin ^{[6
]}

Vose, Julie M. ^{[7
]}

Bast, Martin A. ^{[7
]}

Fenske, Timothy S. ^{[8
]}

Gari, Swapna Narayana Rao ^{[8
]}

Maddocks, Kami J. ^{[9
]}

Bond, David ^{[9
]}

Bachanova, Veronika ^{[10
]}

Kolla, Bhaskar ^{[10
]}

Chavez, Julio ^{[11
]}

Shah, Bijal ^{[11
]}

Lansigan, Frederick ^{[12
]}

Burns, Timothy F. ^{[12
]}

Donovan, Alexandra M. ^{[12
]}

Wagner-Johnston, Nina ^{[13
]}

Messmer, Marcus ^{[13
]}

Mehta, Amitkumar ^{[14
]}

Anderson, Jennifer K. ^{[14
]}

Reddy, Nishitha ^{[15
]}

Kovach, Alexandra E. ^{[15
]}

Landsburg, Daniel J. ^{[16
]}

Glenn, Martha ^{[17
]}

Inwards, David J. ^{[18
]}

Karmali, Reem ^{[19
]}

Kaplan, Jason B. ^{[19
]}

Caimi, Paolo F. ^{[20
]}

Rajguru, Saurabh ^{[21
]}

Evens, Andrew ^{[22
]}

Klein, Andreas ^{[22
]}

Umyarova, Elvira ^{[23
]}

Pulluri, Bhargavi ^{[23
]}

Amengual, Jennifer E. ^{[24
]}

Lue, Jennifer K. ^{[24
]}

Diefenbach, Catherine ^{[25
]}

Fisher, Richard, I ^{[1
]}

Barta, Stefan K. ^{[1
]}

机构：

[1] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[2] BC Canc, Vancouver, BC, Canada

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Emory Univ, Atlanta, GA 30322 USA

[5] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA

[6] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[7] Univ Nebraska, Canc Ctr, Omaha, NE 68182 USA

[8] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[9] Ohio State Univ, Columbus, OH 43210 USA

[10] Univ Minnesota, Minneapolis, MN USA

[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[12] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA

[13] Johns Hopkins Univ, Baltimore, MD USA

[14] Univ Alabama Birmingham, Canc Ctr, Birmingham, AL USA

[15] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[16] Univ Penn, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA

[17] Huntsman Canc Inst, Salt Lake City, UT USA

[18] Mayo Clin, Rochester, MN USA

[19] Northwestern Univ, Evanston, IL USA

[20] Case Western Reserve Univ, Cleveland, OH 44106 USA

[21] Univ Wisconsin, Madison, WI USA

[22] Tufts Univ, Boston, MA 02111 USA

[23] Univ Vermont, Burlington, VT USA

[24] Columbia Univ, New York, NY USA

[25] NYU, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 06期

关键词：

PROGRESSION-FREE SURVIVAL; INTERNATIONAL PROGNOSTIC INDEX; RANDOMIZED-TRIALS; TRANSPLANTATION; IMMUNOCHEMOTHERAPY; PATHOGENESIS; MULTICENTER; THERAPY; PATTERN; IMPACT;

D O I：

10.1200/JCO.18.00690

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSEMantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger.PATIENTS AND METHODSWe retrospectively studied transplantation-eligible adults age 65 years or younger with newly diagnosed MCL treated between 2000 and 2015. The primary objective was to assess for improved progression-free survival (PFS) with AHCT consolidation and secondarily to assess for improved overall survival (OS). Cox multivariable regression analysis and propensity score-weighted (PSW) analysis were performed.RESULTSData were collected from 25 medical centers for 1,254 patients; 1,029 met inclusion criteria. Median follow-up for the cohort was 76 months. Median PFS and OS were 62 and 139 months, respectively. On unadjusted analysis, AHCT was associated with improved PFS (75 v 44 months with v without AHCT, respectively; P < .01) and OS (147 v 115 months with v without AHCT, respectively; P < .05). On multivariable regression analysis, AHCT was associated with improved PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66; P < .01) and a trend toward improved OS (HR, 0.77; 95% CI, 0.59 to 1.01; P = .06). After PSW analysis, AHCT remained associated with improved PFS (HR, 0.70; 95% CI, 0.59 to 0.84; P < .05) but not improved OS (HR, 0.87; 95% CI, 0.69 to 1.1; P = .2).CONCLUSIONIn this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our findings suggest that in younger, fit patients, AHCT consolidation may improve PFS.

引用

页码：471 / +

页数：17

共 50 条

[41] The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era
Chen, Haizhu
Qin, Yan
Yang, Jianliang
Liu, Peng
He, Xiaohui
Zhou, Shengyu
Zhang, Changgong
Gui, Lin
Yang, Sheng
Shi, Yuankai
LEUKEMIA RESEARCH, 2021, 110
[42] Autologous and Allogeneic Donor Transplantation for Mantle Cell Lymphoma in Rituximab Era: Impact of Pre-Transplant Burden On Survival.
Magnusson, Erik A.
Cao, Qing
Linden, Michael A.
Burns, Linda J.
Weisdorf, Daniel J.
Bachanova, Veronika
BLOOD, 2012, 120 (21)
[43] Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma
Bauwens, D
Maerevoet, M
Michaux, L
Theate, I
Hagemeijer, A
Stul, M
Straetmans, N
Leveugle, P
Costantini, S
Ferrant, A
Van den Neste, E
ANNALS OF ONCOLOGY, 2005, 16 : 169 - 169
[44] Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma
Bauwens, D
Maerevoet, M
Michaux, L
Théate, I
Hagemeijer, A
Stul, M
Danse, E
Costantini, S
Vannuffel, P
Straetmans, N
Vekemans, MC
Deneys, V
Ferrant, A
Van Den Neste, E
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (03) : 338 - 340
[45] Maintenance rituximab in mantle-cell lymphoma
Burki, Talha Khan
LANCET ONCOLOGY, 2017, 18 (11): : E647 - E647
[46] Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era
Chiappella, Annalisa
Puccini, Benedetta
Rossi, Marianna
Ferrero, Simone
Arcaini, Luca
Audisio, Ernesta
Baldi, Ileana
Boccomini, Carola
Botto, Barbara
Alberto, Fabbri
Frairia, Chiara
Freilone, Roberto
Ladetto, Marco
Novero, Domenico
Paulli, Marco
Pregno, Patrizia
Priolo, Giorgio
Rigacci, Luigi
Vitolo, Umberto
BLOOD, 2009, 114 (22) : 1144 - 1144
[47] Bendamustine-rituximab in mantle cell lymphoma
Lipsky, Andrew
Martin, Peter
LANCET HAEMATOLOGY, 2017, 4 (01): : E2 - E3
[48] Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis
Schulz, Holger
Bohlius, Julia F.
Trelle, Sven
Skoetz, Nicole
Reiser, Marcel
Kober, Thilo
Schwarzer, Guido
Herold, Michael
Dreyling, Martin
Hallek, Michael
Engert, Andreas
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (09): : 706 - 714
[49] Autologous Transplantation in First Remission in the Rituximab Era in Patients with Mantle Cell Lymphoma: Experience from the Royal Marsden Hospital
Mir, Farheen
Robinson, Anna
Ethell, Mark Edward
Potter, Michael
Nicholson, Emma
Anthias, Chloe
Easdale, Sandra
Gonzalez-Arias, Carlos
Sud, Amit
Dearden, Claire E.
Chau, Ian
Cunningham, David
El-Sharkawi, Dima
Sharma, Bhupinder
Iyengar, Sunil
BLOOD, 2022, 140 : 9366 - 9367
[50] Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma
Kang, Byung Woog
Sohn, Sang Kyun
Moon, Joon Ho
Chae, Yee Soo
Kim, Jong Gwang
Lee, Soo Jung
Kim, Won Seog
Lee, Je-Jung
Lee, Se Ryeon
Park, Keon Uk
Lee, Ho Sup
Lee, Won Sik
Won, Jong-Ho
Park, Moo-Rim
Kwak, Jae-Yong
Kim, Min Kyoung
Kim, Hyo Jung
Oh, Sung Yong
Kang, Hye Jin
Suh, Cheolwon
BLOOD RESEARCH, 2014, 49 (01) : 15 - 21

← 1 2 3 4 5 →